Planning a Medical Device Clinical Trial: How to Avoid Common Startup Mistakes

Clinical ResearchCRO ServicesClinical OperationsMedical DevicesRegulatory Strategy

Oct 12

Planning a medical device clinical trial involves far more than writing a protocol and selecting sites.

Before the first patient can be enrolled, sponsors need to align clinical objectives with regulatory aims, develop study documentation, select qualified sites and vendors, build and validate electronic data capture infrastructure, establish safety oversight, train all relevant parties and coordinate dozens of interdependent activities.

When those tasks are made too late or in isolation, seemingly small gaps can turn into protocol amendments, site activation delays, unexpected costs, data quality issues, and ultimately, delayed submissions.

Many of these problems are preventable.

Common Clinical Trial Startup Mistakes to Address Before Study Execution Begins

1. Treating the Protocol as the Starting Point

One of the first mistakes sponsors can make is finalizing a protocol before establishing the broader clinical and regulatory strategy.

Before finalizing the protocol, the study team should be able to answer several fundamental questions:

What regulatory pathway are we pursuing?
What clinical evidence will the FDA expect?
What claims do we ultimately want the data to support?
What patient population do we want to be able to treat in the commercial context?
What endpoints will demonstrate meaningful outcomes?
How long should patients be followed?
What evidence may eventually be important for reimbursement?

These decisions are interconnected. Your intended regulatory claims can influence endpoints. Your endpoints influence statistical assumptions and data collection. Your competitive landscape may influence the study population, comparator, and follow-up period.

The goal is to design a study that generates the evidence your product will need for both pre-market and post-market goals.

2. Waiting Too Long to Seek FDA Feedback

Sponsors can invest significant time and resources in a clinical plan only to discover later that the FDA has concerns about the proposed study design, endpoints, statistical methodology, or evidence requirements.

For studies where FDA feedback would be valuable, a Q-Submission can provide an opportunity to discuss the clinical strategy before significant resources are committed.

Early agency feedback can help sponsors evaluate whether the proposed protocol, endpoints, statistical approach, and other elements of the study are aligned with regulatory expectations.

That feedback can be particularly valuable before contracts are finalized, databases are built, and sites begin preparing for activation. Otherwise, rework causes substantial delays and has major cost implications.

3. Underestimating Statistical Planning

Sample size and statistical methodology should not be decisions that are finalized after the rest of the study has been designed.

Primary and secondary endpoints should test clearly defined hypotheses and align with study objectives and intended regulatory claims. The Statistical Analysis Plan should address hypotheses, sample size and power calculations, analysis populations, statistical methods, and the handling of missing data.

An underpowered or poorly structured study can create a fundamental problem: even strong clinical results may not produce the evidence needed to answer the study's intended questions.

Bringing an experienced biostatistician into planning early helps ensure the clinical question, endpoint strategy, data collection, and statistical analysis all work together.

4. Choosing Sites Based on Reputation Instead of Realistic Enrollment Potential

An experienced investigator at a well-known institution may look impressive on a site list, but that does not necessarily mean the site will enroll successfully.

Site feasibility should examine practical considerations such as:

Access to the target patient population
Realistic enrollment potential
Investigator and research experience
Available infrastructure and staff
Competing clinical studies
Previous study performance

Sponsors should also build realistic assumptions around screening rates, eligibility, enrollment, and participant dropout.

Opening more sites isn’t always the solution to slow enrollment. Choosing the right sites and understanding what they can realistically deliver is more important.

5. Bringing in Vendors and Oversight Committees Too Late

Modern clinical trials can involve CROs, EDC vendors, core laboratories, imaging providers, biostatisticians, medical monitors, Clinical Events Committees (CECs), Data Safety Monitoring Boards (DSMBs), and other specialized partners.

Each introduces dependencies.

If responsibilities are unclear, contracts are delayed, systems are not ready, or key committee members are identified too late, one dependency can hold up multiple other startup activities.

Vendor selection should therefore be part of the study startup plan rather than something addressed as individual needs arise. Responsibilities, deliverables, timelines, and communication expectations should be established early.

6. Underestimating How Much Documentation Is Required

A finalized protocol is only one piece of clinical trial documentation.

Depending on the study, sponsors may also need Case Report Forms, an Informed Consent Form, Investigator Brochure, Monitoring Plan, Data Management Plan, Statistical Analysis Plan, Safety Management Plan, CEC or DSMB charters, site materials, and other study-specific documents.

Developing these documents is only part of the workload. They also need multidisciplinary review, approval, version control, and alignment with one another.

For example, the CRFs need to capture the data required by the protocol and statistical plan. The monitoring strategy needs to reflect the study's risks and data requirements. Safety procedures need to clearly define responsibilities and escalation pathways.

Documentation should function as an integrated system, not a collection of independent deliverables.

7. Waiting Until the Last Minute to Build and Validate the Database

Data quality begins before the first patient is enrolled.

The EDC system needs to translate the protocol and CRFs into a functional, compliant system for collecting and managing clinical data. Database configuration, validation rules, user permissions, User Acceptance Testing, and other data management processes all require time.

NMCG's Clinical Trial Readiness Checklist specifically identifies a compliant EDC system as a startup requirement and emphasizes that data integrity and traceability should be built into the system before enrollment.

Waiting until sites are nearly ready to activate can make database development a critical-path activity that delays enrollment.

8. Treating Clinical and Regulatory Planning as Separate Workstreams

A clinical trial isn’t an isolated research exercise. It’s part of a larger product development strategy.

Clinical decisions can affect the IDE strategy, future regulatory claims, submission readiness, reimbursement opportunities, and ultimately commercialization.

Similarly, regulatory feedback may require changes to endpoints, follow-up, patient population, statistical methods, or other elements of trial design.

When clinical and regulatory teams operate independently, sponsors risk discovering these conflicts after important decisions have already been made.

An integrated approach allows regulatory strategy to inform trial design while ensuring the clinical program generates evidence appropriate for the regulatory pathway.

9. Planning for FDA Approval but Not What Comes After It

FDA approval or clearance is an essential milestone, but it’s not the only consideration when designing a clinical evidence strategy.

Sponsors should also consider the competitive product landscape and potential reimbursement requirements while developing the study.

The patient population, endpoints, comparator, follow-up period, and outcomes collected can influence how useful the resulting evidence is after regulatory review.

Considering these questions early doesn’t mean adding unnecessary complexity to every trial. It means understanding the evidence the product may ultimately need and making informed decisions about which questions should be answered by the clinical program.

10. Assuming Startup Activities Can Happen Sequentially

Clinical startup rarely follows a simple sequence in which one task finishes before another begins.

Protocol development affects CRFs and database development. Site selection affects enrollment assumptions. FDA feedback may affect the protocol and statistical plan. Vendor timelines can affect site activation. Contracts and budgets may progress while study documents are still being finalized.

That makes project management critical.

Sponsors should develop a realistic startup timeline that identifies dependencies, critical-path activities, responsible parties, and decision points. Regular communication among the sponsor, CRO, sites, vendors, and other partners helps surface issues while there is still time to address them.

The goal is to keep every task moving toward the same study objective.

Better Startup Planning Reduces Downstream Risk

No clinical trial startup will be completely free of unexpected challenges.

But many of the problems that appear during execution can be traced back to decisions made before enrollment: an endpoint that didn’t fully support the intended claim, a site that couldn’t access enough eligible patients, a database that wasn’t ready, a vendor brought in too late, or a protocol that required amendment after regulatory feedback.

The best time to solve these problems is before they become expensive. That requires sponsors to look at clinical strategy, regulatory planning, statistics, operations, data management, safety, vendors, and reimbursement as interconnected pieces of the same development program.

How NMCG Can Help

Nilo Medical Consulting Group combines regulatory consulting expertise with flexible, full-service CRO support. Our team can help sponsors with clinical strategy, protocol and endpoint development, FDA interactions, biostatistics, study documentation, site and vendor selection, EDC development and data management, monitoring and safety planning, CEC/DSMB management, and ongoing trial oversight.

Whether you need comprehensive CRO support or expertise in specific areas of your study, we can help identify readiness gaps and build a practical path toward startup.